A Study With RBT-1, in Healthy Volunteers and Subjects With Stage 3-4 Chronic Kidney Disease
Status:
Active, not recruiting
Trial end date:
2020-12-31
Target enrollment:
Participant gender:
Summary
This is a Phase 1b, single-center, dose-escalating study to evaluate the safety,
tolerability, and pharmacodynamic effect of RBT-1 in healthy volunteers and in subjects with
stage 3-4 CKD. The following biomarkers will be used as surrogate measures of protective
activity: Haptoglobin, Ferritin, Bilirubin, Hemopexin, IL-10, and Heme Oxygenase-1.
Additionally, the P21 biomarker will be monitored at various points of the study.
Phase:
Phase 1
Details
Lead Sponsor:
Renibus Therapeutics, Inc. Renibus Therapuetics, Inc.
Treatments:
Ferric Oxide, Saccharated Iron Protoporphyrin IX Tin protoporphyrin IX